The Experts below are selected from a list of 2082 Experts worldwide ranked by ideXlab platform
Xiaojun Huang - One of the best experts on this subject based on the ideXlab platform.
-
resistance to Arsenic Therapy in acute promyelocytic leukemia
The New England Journal of Medicine, 2014Co-Authors: Xiaojun HuangAbstract:Although resistance to Arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in PML at the site of Arsenic binding appears to be the main mechanism of resistance.
Michiko Niwakawakita - One of the best experts on this subject based on the ideXlab platform.
-
jak2v617f myeloproliferative neoplasm eradication by a novel interferon Arsenic Therapy involves pml
Journal of Experimental Medicine, 2021Co-Authors: Tracy Dagher, Nabih Maslah, Valerie Edmond, Bruno Cassinat, William Vainchenker, Stephane Giraudier, Florence Pasquier, Emmanuelle Verger, Michiko NiwakawakitaAbstract:Interferon α (IFNα) is used to treat JAK2V617F-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by Arsenic trioxide (ATO) drives eradication of acute promyelocytic leukemia. ATO sharply potentiated IFNα-induced growth suppression of JAK2V617F patient or mouse hematopoietic progenitors, which required PML and was associated with features of senescence. In a mouse MPN model, combining ATO with IFNα enhanced and accelerated responses, eradicating MPN in most mice by targeting disease-initiating cells. These results predict potent clinical efficacy of the IFNα+ATO combination in patients and identify PML as a major effector of Therapy, even in malignancies with an intact PML gene.
Florence Pasquier - One of the best experts on this subject based on the ideXlab platform.
-
jak2v617f myeloproliferative neoplasm eradication by a novel interferon Arsenic Therapy involves pml
Journal of Experimental Medicine, 2021Co-Authors: Tracy Dagher, Nabih Maslah, Valerie Edmond, Bruno Cassinat, William Vainchenker, Stephane Giraudier, Florence Pasquier, Emmanuelle Verger, Michiko NiwakawakitaAbstract:Interferon α (IFNα) is used to treat JAK2V617F-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by Arsenic trioxide (ATO) drives eradication of acute promyelocytic leukemia. ATO sharply potentiated IFNα-induced growth suppression of JAK2V617F patient or mouse hematopoietic progenitors, which required PML and was associated with features of senescence. In a mouse MPN model, combining ATO with IFNα enhanced and accelerated responses, eradicating MPN in most mice by targeting disease-initiating cells. These results predict potent clinical efficacy of the IFNα+ATO combination in patients and identify PML as a major effector of Therapy, even in malignancies with an intact PML gene.
Tracy Dagher - One of the best experts on this subject based on the ideXlab platform.
-
jak2v617f myeloproliferative neoplasm eradication by a novel interferon Arsenic Therapy involves pml
Journal of Experimental Medicine, 2021Co-Authors: Tracy Dagher, Nabih Maslah, Valerie Edmond, Bruno Cassinat, William Vainchenker, Stephane Giraudier, Florence Pasquier, Emmanuelle Verger, Michiko NiwakawakitaAbstract:Interferon α (IFNα) is used to treat JAK2V617F-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by Arsenic trioxide (ATO) drives eradication of acute promyelocytic leukemia. ATO sharply potentiated IFNα-induced growth suppression of JAK2V617F patient or mouse hematopoietic progenitors, which required PML and was associated with features of senescence. In a mouse MPN model, combining ATO with IFNα enhanced and accelerated responses, eradicating MPN in most mice by targeting disease-initiating cells. These results predict potent clinical efficacy of the IFNα+ATO combination in patients and identify PML as a major effector of Therapy, even in malignancies with an intact PML gene.
Kenneth C. Anderson - One of the best experts on this subject based on the ideXlab platform.
-
History of the Development of Arsenic Derivatives in Cancer Therapy
The Oncologist, 2001Co-Authors: Samuel Waxman, Kenneth C. AndersonAbstract:Arsenic is a natural substance that has been used medicinally for over 2,400 years. In the 19th century, it was the mainstay of the materia medica. A solution of potassium arsenite (Fowler's solution) was used for a variety of systemic illnesses from the 18th until the 20th century. This multipurpose solution was also primary Therapy for the treatment of chronic myelogenous leukemia until replaced by radiation and cytotoxic chemoTherapy. The past 100 years have seen a precipitous decline in Arsenic use and, by the mid-1990s, the only recognized indication was the treatment of trypanosomiasis. Much of this decline was due to concerns about the toxicity and potential carcinogenicity of chronic Arsenic administration. The rebirth of Arsenic Therapy occurred in the 1970s when physicians in China began using Arsenic trioxide as part of a treatment for acute promyelocytic leukemia (APL). Their accumulated experience showed that a stable solution of Arsenic trioxide given by intravenous infusion was remarkably safe and effective both in patients with newly diagnosed APL leukemia and in those with refractory and relapsed APL. The mechanisms of action of Arsenic derivatives in this disease and other malignancies are many and include induction of apoptosis, partial cytodifferentiation, inhibition of proliferation, and inhibition of angiogenesis. Molecular studies and ongoing clinical trials suggest that, as a chemotherapeutic agent, Arsenic trioxide shows great promise in the treatment of malignant disease.